Clinical Trials at Retina-Vitreous Associates Medical Group
The physicians at Retina-Vitreous Associates Medical Group are involved in clinical research potentially leading to the development of new diagnostic and therapeutic modalities for retinal disease. Retina-Vitreous Associates Medical Group participates in most clinical trials assessing new therapies for macular degeneration and diabetic retinopathy amongst other retinal diseases. Currently enrolling clinical trials center on patients with diagnoses of:
- Wet AMD, treatment naïve patients and patients who have had AMD treatments
- Diabetic Retinopathy
- Central Retinal Vein Occlusion
- Retinitis Pigmentosa
- Geographic Atrophy
- Polypoidal Choroidal Vasculopathy
- Rhegmatogenous Macula-Off Retinal Detachment
Our clinical trials department can be contacted directly at
(310) 289-2478 [option 3].
Currently enrolling clinical trials:
(Further information is available by clicking on the name of the clinical trial. Scroll down to view the complete listing of currently enrolling clinical trials. However, please note that not all clinical trials have a corresponding website.)
Wet Age-Related Macular Degeneration - (treatment Naïve)
- Genentech HARBOR: A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
Wet Age-Related Macular Degeneration - (previously treated)
- Novartis CRAD001A2203: A Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy of Oral Everolimus, Either Alone or Added to Lucentis, in Patients With Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
- Novartis AIM SPP100A2244: A Randomized, Double-masked, Placebo-controlled, add-on Study to Assess the Efficacy of Oral Aliskiren 300 mg Once Daily for Diabetic Macular Edema
- The READ 3 Study NCT01077401: Ranibizumab for Edema of the mAcula in Diabetes: Protocol 3 With High Dose - the READ 3 Study
Retinal Vein Occlusion
- Regeneron Pharmaceuticals VGFT-OD-0819: A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion
Geographic Atrophy
- No open trials at the moment
Retinitis Pigmentosa
- No open trials at the moment
Polypoidal Choroidal Vasculopathy
- Oxigene OXC402-201: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Biological Effects of Intravenous Fosbretabulin in Asian Subjects With Polypoidal Choroidal Vasculopathy (PCV)
Rhegmatogenous Macula-Off Retinal Detachment
- Allergan 190342-031D: A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 3 Month Study with a 9-Month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDSR) Applicator System in Improving Visual Function in Patients with a Previous Rhegmatogenous Macula-Off Retinal Detachment
Optic Nerve Atrophy
- Protocol Quark .007: A Phase I, Open-label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients with Optic Nerve Atrophy (Stratum I)